| 1. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 2. |
- Capdevila, S., et al.
(författare)
-
RFID based probes for EM-field measurements
- 2009
-
Ingår i: European Conference on Antennas and Propagation, EuCAP 2009, Proceedings. - : IEEE. - 9783000245732 ; , s. 2787-2790
-
Konferensbidrag (refereegranskat)abstract
- In this paper the use of RFID for EM field measurement is studied. A novel RFID antenna with high tuning capabilities is presented and measured, and it is used in combination with several RFID IC to measure the EM field along the H-plane of a horn antenna. A calibration procedure for the non-linear effects in RFID IC is introduced and used to correct the measured fields.
|
|
| 3. |
- Gonzalez-Granadillo, G, et al.
(författare)
-
Automated Cyber and Privacy Risk Management Toolkit
- 2021
-
Ingår i: Sensors (Basel, Switzerland). - : MDPI AG. - 1424-8220. ; 21:16
-
Tidskriftsartikel (refereegranskat)abstract
- Addressing cyber and privacy risks has never been more critical for organisations. While a number of risk assessment methodologies and software tools are available, it is most often the case that one must, at least, integrate them into a holistic approach that combines several appropriate risk sources as input to risk mitigation tools. In addition, cyber risk assessment primarily investigates cyber risks as the consequence of vulnerabilities and threats that threaten assets of the investigated infrastructure. In fact, cyber risk assessment is decoupled from privacy impact assessment, which aims to detect privacy-specific threats and assess the degree of compliance with data protection legislation. Furthermore, a Privacy Impact Assessment (PIA) is conducted in a proactive manner during the design phase of a system, combining processing activities and their inter-dependencies with assets, vulnerabilities, real-time threats and Personally Identifiable Information (PII) that may occur during the dynamic life-cycle of systems. In this paper, we propose a cyber and privacy risk management toolkit, called AMBIENT (Automated Cyber and Privacy Risk Management Toolkit) that addresses the above challenges by implementing and integrating three distinct software tools. AMBIENT not only assesses cyber and privacy risks in a thorough and automated manner but it also offers decision-support capabilities, to recommend optimal safeguards using the well-known repository of the Center for Internet Security (CIS) Controls. To the best of our knowledge, AMBIENT is the first toolkit in the academic literature that brings together the aforementioned capabilities. To demonstrate its use, we have created a case scenario based on information about cyber attacks we have received from a healthcare organisation, as a reference sector that faces critical cyber and privacy threats.
|
|
| 4. |
|
|
